BTK Inhibitors in CLL: New Clinical Evidence Reshapes First-Line Treatment Please like and subscribe if you enjoyed this video :-) Introduction The treatment landscape for chronic lymphocytic leukemia (CLL), the most common leukemia in Western countries, has undergone a major shift with the advent of Bruton’s tyrosine kinase
Author: Nancy Ogbonna
VEXAS Syndrome: The Newly Discovered Disorder Every Hematologist Should Know
VEXAS Syndrome: The Newly Discovered Disorder Every Hematologist Should Know Check back later for a possible video summary. Videos are created for most articles. Abstract This paper provides a comprehensive review of VEXAS syndrome; a newly recognized, adult-onset autoinflammatory condition with a genetic basis and complex multisystem involvement, carrying significant implications for hematologists, rheumatologists, and other specialists. First
Plasmapheresis in TTP Mimics: When Are We Getting It Wrong?
Plasmapheresis in TTP Mimics: When Are We Getting It Wrong? Check back later for a possible video summary. Videos are created for most articles. Introduction Plasmapheresis has revolutionized the treatment of thrombotic thrombocytopenic purpura (TTP), reducing mortality rates from nearly 100% to less than 10–20%. Despite this progress, diagnostic uncertainty remains a
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond
Monoclonal Antibodies in Relapsed Multiple Myeloma: The Era of Bispecifics and Beyond Check back later for a possible video summary. Videos are created for most articles. Abstract This paper provides an in-depth review of monoclonal antibody (mAb) therapies in the treatment of relapsed multiple myeloma (MM), with a particular focus on bispecific antibodies
Thrombocytopenia in the ICU: Essential Guide for Clinical Hematologists
Thrombocytopenia in the ICU: Essential Guide for Clinical Hematologists Please like and subscribe if you enjoyed this video :-) Introduction Thrombocytopenia is a frequent hematologic abnormality in critically ill patients, affecting up to 67.6% at ICU admission, with an additional 14–44% developing it during their stay.
Hidden Signs of GATA2 Deficiency: Why Doctors Miss This Rare Disorder
Hidden Signs of GATA2 Deficiency: Why Doctors Miss This Rare Disorder Check back later for a possible video summary. Videos are created for most articles. Introduction GATA2 deficiency is the most common hereditary predisposition to pediatric myelodysplastic syndrome (MDS), yet it remains one of the most frequently overlooked genetic disorders in clinical practice. This
Vitamin D Levels Linked to Neuropsychiatric Outcomes
Cancer Vaccines for Treatment: Breaking Through Scientific Barriers in 2025
Smart Devices Detect Early Cognitive Decline
CDC Bird Flu Alert: Why Human Cases Have Suddenly Dropped in 2025
